Abstract
BLOCKADE of CD28/B7 and/or CD40/CD40L pathways has been employed with reasonable success to prevent organ allograft rejection.1.:! Additionally, contemporaneous but not discrete use of rhCfLA4-Ig and antiCD40L monoclonal antibody (MAb) has also been shown to prevent chronic rejection.1.3 In the realm of cellular transplantation (Tx), it has been reported that the use of either rhCfLA4-Ig or anti-CD40L MAb alone resulted in prolongation but not indefinite survival of islet allografts.4 ,5 Based on these observations, we hypothesized that combined transient perioperative blockade of both costimulatory pathways would result in indefinite islet allograft survival, thus allowing maintenance of euglycemia in a diabetic recipient without the need for exogenous insulin. This latter tenet was tested in an MHC-incompatible mouse model of islet cell Tx; the outcome of this novel study is presented herein.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
